The best prescription medicine for weight loss for most people is tirzepatide (Zepbound) or semaglutide (Wegovy), the two most effective FDA-approved options, producing roughly 15 to 21 percent and about 15 percent average total body weight loss in trials. Other approved medicines, including phentermine-topiramate, naltrexone-bupropion, phentermine, liraglutide, and orlistat, have a role too, and the right choice depends on your other health conditions, contraindications, cost, and preferences. There is no single best medicine for everyone, which is exactly why this is a medical decision.
This guide ranks the approved weight loss treatments by effectiveness, explains how the diabetes medicines fit in, and walks through how clinicians actually match a medicine to a patient. Everything here is educational, results vary, and any treatment should be started with a licensed healthcare provider.
The American Gastroenterological Association strongly recommends adding medication to lifestyle changes for adults with a BMI of 30 or higher, or 27 or higher with weight-related complications, when lifestyle efforts alone have not been enough. It supports semaglutide, liraglutide, phentermine-topiramate, and naltrexone-bupropion based on moderate-certainty evidence, and phentermine and diethylpropion based on lower-certainty evidence. It suggests against orlistat. The table below shows the average weight loss expected after 12 months for each approved medicine.
| Medication | Avg. weight loss (12 mo) | How it works |
| Tirzepatide (Zepbound) | 15 to 20% | Dual GIP/GLP-1 receptor agonist |
| Semaglutide (Wegovy) | About 15% | GLP-1 receptor agonist |
| Diethylpropion | About 10% | Sympathomimetic (appetite suppressant) |
| Phentermine-topiramate (Qsymia) | 8 to 10% | Sympathomimetic plus carbonic anhydrase inhibitor |
| Phentermine | About 7% | Sympathomimetic (short-term) |
| Naltrexone-bupropion (Contrave) | About 5% | Dopamine/norepinephrine plus opioid antagonist |
| Liraglutide (Saxenda) | About 5 to 8% | GLP-1 receptor agonist |
| Orlistat (Xenical / Alli) | About 3% | Intestinal lipase inhibitor |
Effectiveness is only part of the picture, but it is a useful starting point. The newer incretin-based medicines sit clearly at the top, followed by the older centrally acting agents, with orlistat at the bottom. All of them are meant to be used with a reduced-calorie diet and more physical activity, not in place of them; the trial results that produced these figures were all achieved with lifestyle support built in.
Wondering which prescription weight loss medicine you may be eligible for?
→ See if you qualify
If you are asking what the strongest weight loss prescription is, the answer is the incretin-based injectables, the most effective class available.
Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist given as a weekly injection. In the SURMOUNT-1 trial, average weight loss was 15.0 percent at the 5 mg dose, 19.5 percent at 10 mg, and 20.9 percent at 15 mg, versus 3.1 percent on placebo at 72 weeks. The head-to-head SURMOUNT-5 trial showed it produced more weight loss than semaglutide, making it the most effective single agent.
Semaglutide (Wegovy) is a GLP-1 receptor agonist, also a weekly injection. In the STEP-1 trial, average weight loss was 14.9 percent versus 2.4 percent on placebo at 68 weeks, and about 86 percent of patients lost at least 5 percent of body weight. It is also approved to reduce cardiovascular risk in people with established heart disease and obesity, and a once-daily 25 mg oral tablet was approved in December 2025.
Liraglutide (Saxenda) is an older daily GLP-1 injection that produces about 8 percent weight loss. It is less effective than the other two but remains an option.
All GLP-1-based medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2, and their most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually mild to moderate during dose increases.
Beyond the incretin medicines, several older prescription weight loss treatments remain useful, especially when matched to the right patient.
Phentermine-topiramate (Qsymia): about 8 to 10 percent weight loss, among the more effective options. It is particularly useful for people who also have migraines, but it is teratogenic, so it is contraindicated in pregnancy and requires monthly pregnancy testing.
Naltrexone-bupropion (Contrave): about 5 to 6 percent weight loss. It may be preferred for people with depression, or those trying to quit smoking or reduce alcohol use. It is contraindicated in seizure disorders, eating disorders, and with opioid use, and can raise blood pressure slightly.
Phentermine alone: about 7 percent weight loss, approved for short-term use (up to 12 weeks) and low in cost. It is contraindicated in cardiovascular disease and uncontrolled high blood pressure.
Orlistat (Xenical, or Alli over the counter): about 3 percent weight loss. Guidelines suggest against it because of its modest effect and frequent digestive side effects, though it can have a niche role for people who also need LDL cholesterol lowering.
A common point of confusion is the overlap between diabetes medicines and weight loss medicines. Semaglutide and tirzepatide are sold under different brand names depending on the approved use. Wegovy and Zepbound are approved for weight management, while Ozempic and Mounjaro are the same molecules approved for type 2 diabetes. In people with diabetes, these are excellent choices because they improve blood sugar and support weight loss at the same time, which is why a GLP-1 or dual agonist is often the best diabetes drug for weight loss.
Two important clarifications. First, using the diabetes-branded versions (Ozempic, Mounjaro) purely for weight loss in someone without diabetes is off-label; the weight-approved versions are Wegovy and Zepbound. Second, Rybelsus is the oral tablet form of semaglutide approved for type 2 diabetes, so using Rybelsus for weight loss is also off-label. The oral medicine actually approved for weight management is the newer once-daily semaglutide 25 mg tablet (Wegovy). A provider can explain which version is appropriate and approved for your situation.
Choosing a weight loss medicine is about matching the drug to the person. Clinicians individualize the choice based on your other conditions, contraindications, cost, and preferences:
Effectiveness is typically reassessed at three months. If you have not lost at least 5 percent of your body weight by then, guidelines advise stopping that medicine and trying an alternative rather than continuing something that is not working.
Cost and access are part of the real-world decision too. The newer incretin medicines are the most effective but also the most expensive, and insurance coverage varies widely, while phentermine and phentermine-topiramate are far cheaper. Sometimes the best medicine on paper is not the one a particular person can realistically obtain and stay on month after month, so an honest conversation about budget and coverage is part of choosing well. A medically supervised program can help you weigh effectiveness against cost and find an option you can sustain.
See whether one of these medicines fits your health history, guided by a licensed provider.
→ Take the 2-minute eligibility quiz
Weight loss with any of these medicines builds gradually over months as the dose is increased, rather than overnight. The figures above are clinical trial averages, and your own response may be higher or lower. Side effects, mainly gastrointestinal with the incretin medicines, tend to be most noticeable during dose increases and ease over time.
Obesity is a chronic disease, and weight regain is common after stopping, as shown in the STEP-4 and SURMOUNT-4 trials. For that reason, these medicines are generally intended for long-term use when they are tolerated and effective. Stopping is a decision to make with your provider, who can help plan how to maintain your results. Talk to a healthcare provider about which medicine, if any, is right for you.
See which weight loss medicine could be right for you. It takes about two minutes.
→ Check your eligibility
What is the strongest weight loss prescription?
Tirzepatide (Zepbound) produces the greatest average weight loss of the FDA-approved medicines, followed by semaglutide (Wegovy). Both are weekly injections. Among pills, the oral semaglutide tablet and phentermine-topiramate are the strongest. The best choice still depends on your health and is a decision for a provider.
What is the best diabetes drug for weight loss?
Semaglutide and tirzepatide, the GLP-1 and dual GIP/GLP-1 agonists, are the most effective for people with type 2 diabetes because they improve blood sugar and support weight loss. The diabetes-branded versions (Ozempic, Mounjaro) used for weight loss without diabetes are off-label; the weight-approved versions are Wegovy and Zepbound.
Can you use Rybelsus for weight loss?
Rybelsus is oral semaglutide approved for type 2 diabetes, so using it for weight loss is off-label. The oral medicine approved for weight management is the newer once-daily semaglutide 25 mg tablet (Wegovy). A provider can advise on the right option.
How long do you take weight loss medicine?
Because weight regain is common after stopping, these are generally long-term medicines used as long as they are tolerated and effective. Effectiveness is checked at three months, and treatment is adjusted if you have not lost at least 5 percent of body weight.
Are prescription weight loss medicines safe?
They are considered safe for appropriate candidates under medical supervision, but each has specific contraindications and side effects. The incretin medicines carry a boxed warning about thyroid C-cell tumors. A full medical review is part of starting any of them.
Learn more: FDD Weight Loss Program | Eligibility quiz
